UNSPSC 51143705: Benactyzine/meprobamate

This classification denotes a combination drug defined by the U.S. Department of Veterans Affairs in its (VA's) National Drug File (NDF), which falls under VA Drug Class CN900. This VA Drug Class (CN900) classifies this compound as belonging to the group CNS MEDICATIONS, OTHER.

UNSPSC 51143705 Benactyzine/meprobamate is a Commodity code with minimal recent state and local procurement activity directly matching its nominal pharmaceutical scope. The three recent opportunities tagged to this code address naloxone and drug deactivation systems, a direct-to-manufacturer prescription program RFI, and generic multi-source pharmaceuticals and OTC products—none of which center on benactyzine/meprobamate specifically. State and local purchasing bodies soliciting under this code span county health departments (Seminole County, Florida), state health and human services commissions (Texas HHS), and multistate cooperative purchasing alliances (Minnesota MMCAP), though the opportunities present do not demonstrate a sustained procurement pattern for the benactyzine/meprobamate combination product itself.

The geographic spread of tagged opportunities includes Florida, Texas, and Minnesota, with the Minnesota MMCAP RFP extending participation to Oregon and other member states. Representative recent solicitations include Seminole County's IFB 60459723LAS (posted June 30, 2026, response due July 26, 2023) for naloxone and drug deactivation systems with quarterly deliveries; the Texas HHS Commission's RFI HHS0017013 (posted April 3, 2026) exploring direct-to-manufacturer prescription programs; and the Minnesota MMCAP RFP S1070000015802 (posted January 20, 2026, proposals due March 26, 2026) for generic multi-source pharmaceuticals and OTC products through authorized wholesalers. The mismatch between the code's benactyzine/meprobamate designation and the actual scope of recent opportunities suggests this code sees limited relevant procurement activity in current state and local markets, making it a lower-priority pursuit target absent direct vendor relationships in the specific formulation and indication space.